Last updated: February 27, 2026
What is NDC 70677-1226?
NDC 70677-1226 refers to a specific medication listed in the National Drug Code directory. Based on available data, this NDC corresponds to Tildrakizumab (brand name: Ilumya), approved by the FDA for the treatment of moderate to severe plaque psoriasis in adults.
Market Overview
Product Status and Approval
- FDA Approval Date: March 2018
- Indications: Moderate to severe plaque psoriasis
- Manufacturers: Sun Pharmaceutical Industries
- Formulation: Subcutaneous injection, typically administered every 12 weeks after initial doses
Market Size and Demand Drivers
- Global psoriasis market estimated at $11.3 billion in 2022
- US market share constitutes approximately 45-50% of this total
- Prevalence of plaque psoriasis in the US: roughly 2.2% of adults (~5 million people), with treatment eligible for about 1.7 million
Competitive Landscape
Major competitors include:
| Drug Name |
Mechanism |
Market Share (2022) |
Price Range (per dose) |
Key Differentiators |
| Adalimumab (Humira) |
TNF-alpha inhibitor |
45% |
$2,600–$3,300 |
Established, long approval history |
| Secukinumab (Cosentyx) |
IL-17A inhibitor |
25% |
$4,000–$4,600 |
High efficacy, rapid onset |
| Ustekinumab (Stelara) |
IL-12/23 inhibitor |
15% |
$3,300–$4,000 |
Longer dosing interval |
| Tildrakizumab (Ilumya) |
IL-23 inhibitor |
5–7% |
~$1,600–$2,000 per dose |
Cost advantage, favorable safety profile |
Pricing Trends
- The average wholesale price (AWP) for Tildrakizumab is approximately $1,600–$2,000 per dose
- Insurance reimbursement typically reduces patient out-of-pocket costs to $30–$80, depending on coverage
- Pricing adjustments depend on formulary status, negotiated discounts, and regional policies
Price Projections and Market Dynamics
Short-Term (Next 1–2 Years)
- Price stability expected due to established patent exclusivity until 2027
- Market penetration continues slowly; Tildrakizumab holds less than 10% of the market
- Competitive pressures from newer biologics and biosimilars influence pricing but are limited by patent protections
Medium to Long-Term (3–5 Years)
- Patent expiration forecasted for 2027, which could induce price erosion
- Biosimilar entry likely post-2027 could reduce prices by 20–40%
- Market growth driven by increasing psoriasis prevalence and expanding indications (e.g., psoriatic arthritis)
- Pricing could decline to approximate $1,200–$1,500 per dose within 3–5 years after patent expiry
Price Sensitivity and Access
- Payor policies favor lower-cost biologics, which could pressure price reductions
- Contracting and formulary placements influence actual transaction prices
- Patient assistance programs mitigate cost concerns but do not directly impact market prices
Revenue Estimates
| Year |
Estimated Units Sold |
Average Price per Dose |
Estimated Revenue (USD millions) |
| 2022 |
150,000 |
$1,800 |
$270 |
| 2023 |
180,000 |
$1,800 |
$324 |
| 2024 |
200,000 |
$1,750 |
$350 |
| 2025 |
220,000 |
$1,700 |
$374 |
| 2026 |
240,000 |
$1,500 |
$360 |
(Assumptions: steady growth driven by market expansion, price adjustments near patent expiry)
Key Takeaways
- NDC 70677-1226, identified as Tildrakizumab (Ilumya), occupies a niche in the psoriasis biologics market.
- Its pricing remains competitive, primarily influenced by market share and competition rather than cost.
- Price erosion is anticipated around 2027 when patent protection ends and biosimilars emerge.
- Revenue projections highlight moderate growth with slight downward price pressure over the next five years.
- Payers and formulary decisions will significantly influence actual transaction prices and patient access.
FAQs
1. What factors influence the price of Tildrakizumab?
Market competition, patent status, manufacturer negotiations, and payer policies impact its price.
2. When will biosimilars likely enter the market?
Potential biosimilar entry is expected post-2027, following patent expiration.
3. How does Tildrakizumab compare in efficacy to other biologics?
It shows comparable efficacy to other IL-23 inhibitors with a favorable safety profile but may have a slower onset compared to IL-17 inhibitors.
4. Which markets are most lucrative for Tildrakizumab?
The US and European markets dominate, due to higher prevalence of psoriasis and payer infrastructure.
5. How might new indications affect price projections?
Expansion into psoriatic arthritis or other autoimmune conditions could increase demand without significantly affecting unit price unless new competition arises.
References
[1] IQVIA. (2022). Global biologics market analysis.
[2] FDA. (2018). Tildrakizumab (Ilumya) approval announcement.
[3] FirstBridge. (2022). Psoriasis market report.
[4] SSR Health. (2022). Biologic drug pricing and reimbursement data.
[5] Bioequity Research. (2023). Biosimilar market forecasts.
Note: Data are estimates based on publicly available industry reports, patent timelines, and market surveys.
